山西振东制药股份有限公司 2020 年第三季度报告全文 山西振东制药股份有限公司 2020 年第三季度报告 2020-070 2020 年 10 月 1 山西振东制药股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李安平、主管会计工作负责人刘长禄及会计机构负责人(会计主 管人员)刘长禄声明：保证季度报告中财务报表的真实、准确、完整。 2 山西振东制药股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|--------|-------|-----------------------------------------------------|-------------- ...

山西振东制药股份有限公司 2020 年半年度报告全文 山西振东制药股份有限公司 2020 年半年度报告 2020-061 2020 年 08 月 1 山西振东制药股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人李安平、主管会计工作负责人刘长禄及会计机构负责人(会计主 管人员)刘长禄声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 | --- | |------------------------------------------------------------------------| | | | 1 、政策风险。新版《药品管理法》于 2019 年 12 月 1 日正式执行，重新定 | | 义了假药、劣药，并加大了违法处罚力度，责任落实到人。同时取消了 | | 认证，意味着药品生产监管更加严格，各类监督检查、抽检、飞检的频率加大。 | | 公司现有品种数和剂型数在山西省 ...

山西振东制药股份有限公司 2020 年第一季度报告全文 山西振东制药股份有限公司 2020 年第一季度报告 2020-041 2020 年 04 月 1 山西振东制药股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李安平、主管会计工作负责人刘长䘵及会计机构负责人(会计主 管人员)刘长䘵声明：保证季度报告中财务报表的真实、准确、完整。 2 山西振东制药股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-----------------------------------------------------|-------|-------|------------------|-------| ...

山西振东制药股份有限公司 2019 年年度报告全文 山西振东制药股份有限公司 2019 年年度报告 2020-024 2020 年 04 月 1 山西振东制药股份有限公司 2019 年年度报告全文 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人李安平、主管会计工作负责人刘长禄及会计机构负责人(会计主 管人员)刘长禄声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 、政策风险。新版《药品管理法》于 年 月 日正式执行，重新定 | --- | |------------------------------------------------------------------------| | | | 1 2019 12 1 | | 义了假药、劣药，并加大了违法处罚力度，责任落实到人。同时取消了 | | 认证，意味着药品生产监管更加严格，各类监督检查、抽检、飞检的频率加大。 | | 公司现有品种数和剂型数在山西省均位于前列，外部 ...

山西振东制药股份有限公司 2019 年第三季度报告全文 山西振东制药股份有限公司 2019 年第三季度报告 2019-065 2019 年 10 月 1 山西振东制药股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李安平、主管会计工作负责人刘长䘵及会计机构负责人(会计主 管人员)刘长䘵声明：保证季度报告中财务报表的真实、准确、完整。 2 山西振东制药股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|--------|-----------------------------------------------------|-------|-------------- ...

山西振东制药股份有限公司 2019 年半年度报告全文 山西振东制药股份有限公司 2019 年半年度报告 2019-046 2019 年 08 月 1 山西振东制药股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人李安平、主管会计工作负责人刘长禄及会计机构负责人(会计主 管人员)刘长禄声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 1、行业政策变化带来的风险。近年来，随着医药体制改革不断深入，国家 对医药行业的管理力度不断加大。药品审批、质量监管、药品招标、公立医院 改革、医保控费、两票制、药品集中带量采购等系列政策措施的实施，为整个 医药行业的未来发展带来重大影响，使公司面临行业政策变化带来的风险。 2、药品研发创新及仿制药一致性评价的风险。医药行业创新具有投入大、 周期长、高风险的特点，产品从研发到上市需要耗费 10 年甚至更多的时间， 这期间任何决策的偏差、技术上的失误都 ...

证券代码：300158 证券简称：振东制药 公告编号：2019-035 山西振东制药股份有限公司 关于召开 2018 年度业绩说明会暨投资者网上集体 接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： ●会议召开时间：2019 年 5 月 23 日（星期四）下午 14:30 至 16:30 ●会议召开方式：网络方式 一、说明会类型 本次说明会为山西振东制药股份有限公司（以下简称"公司"） 2018 年度业绩网上说明会。公司已于 2018 年 4 月 25 日在《中国 证券报》、《上海证券报》、《证券时报》及上海证券交易所网站 (www.sse.com.cn)刊登了 2018 年年度报告。为使广大投资者能更全 面深入地了解公司经营业绩等具体情况，公司根据山西省证监局《关 于举办山西辖区上市公司 2019年度投资者网上集体接待日暨上市公 司专题培训的通知》，公司决定通过网络平台交流方式举行"2018 年 度业绩说明会暨投资者网上集体接待日活动"。 二、说明会召开的时间 公司 2018 年度业绩网上说明会将于 2019 年 5 月 23 ...

Financial Performance - Total operating revenue for Q1 2019 was ¥898,702,801.66, representing a 16.32% increase compared to ¥772,622,450.52 in the same period last year[8]. - Net profit attributable to shareholders was ¥51,454,763.17, a 1.59% increase from ¥50,647,976.74 in the previous year[8]. - Basic earnings per share for Q1 2019 was ¥0.0501, slightly up by 1.62% from ¥0.0493 in the previous year[8]. - The company achieved operating revenue of 898.70 million yuan, representing a year-on-year growth of 16.32%[25]. - The net profit attributable to shareholders was 51.45 million yuan, an increase of 1.59% compared to the same period last year[25]. - The company reported a gross margin of 45% for Q1 2019, indicating strong operational efficiency[34]. - The company reported a significant increase in revenue for Q1 2019, with a year-over-year growth of 15%[49]. - The company provided a positive outlook for the next quarter, projecting a revenue increase of 10% to 12%[53]. Cash Flow and Liquidity - Net cash flow from operating activities improved significantly to ¥9,428,578.15, compared to a negative cash flow of ¥-179,362,851.21 in the same period last year, marking a 105.26% increase[8]. - Cash flow from operating activities for Q1 2019 was CNY 9,428,578.15, a significant improvement from a negative cash flow of CNY -179,362,851.21 in the previous year[116]. - Cash inflow from operating activities totaled CNY 996,928,630.61, up from CNY 954,503,531.37 in Q1 2018, representing an increase of 4.46%[116]. - Cash outflow from operating activities decreased to CNY 987,500,052.46 from CNY 1,133,866,382.58, a reduction of 12.91%[116]. - The company reported a cash and cash equivalents balance of $235,474,091.45 at the end of the period, up from $204,224,997.72 at the beginning[122]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,349,002,483.41, reflecting a 1.89% increase from ¥7,212,538,342.16 at the end of the previous year[8]. - The company's total liabilities increased to ¥1,937,074,938.75 from ¥1,850,124,230.17, reflecting a growth of approximately 4.7%[95]. - Current liabilities rose to CNY 1,526,923,130.08 from CNY 1,440,431,003.27, an increase of about 6.1%[95]. - The total equity of the company reached ¥4,959,919,937.25, a slight increase from ¥4,948,871,937.01 year-on-year[104]. - The company's accounts receivable totaled $1,384,385,374.23, indicating a significant amount of outstanding payments[124]. Research and Development - Research and development expenses for the first quarter amounted to 17.59 million yuan, up 34.60% year-on-year, primarily due to increased costs for generic drug consistency evaluation and clinical trials[23]. - The company has invested a total of 4,742,000 CNY in R&D for various drugs, including 3,742,000 CNY for Lapatinib raw materials and formulations[28]. - Research and development investments increased by 30% in Q1 2019, focusing on innovative drug formulations[59]. Strategic Initiatives - The company is focusing on the "big health industry" and optimizing its business strategy to achieve steady growth[26]. - The company is actively promoting OTC channel marketing and advertising, enhancing brand awareness, and advancing consistency evaluations[28]. - A strategic acquisition of a local pharmaceutical company is in progress, expected to enhance the company's product portfolio and distribution network[34]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of $50 million allocated for this purpose[61]. Risks and Challenges - The company faces risks from national policy changes, including drug price regulation and centralized procurement, which could impact future development[30]. - The concentration of revenue from key products like Longdi Calcium and compound injections poses a risk to the company's financial performance[30]. - The company is committed to improving R&D capabilities and project management to mitigate risks associated with new drug development[30]. Government Support and Compliance - The company received government subsidies amounting to ¥5,160,230.35 during the reporting period[8]. - The company is committed to maintaining compliance with regulatory standards, ensuring transparency in all financial disclosures[49]. - The company has not reported any violations regarding external guarantees during the reporting period, indicating a stable financial position[87].

Economic Environment and Industry Challenges - The pharmaceutical industry is facing significant pressure due to a slowdown in national economic growth, with increased scrutiny and regulatory requirements impacting production costs and operational risks [7]. - The company acknowledges the risk of goodwill impairment following acquisitions if the expected operational performance of acquired entities is not met [8]. - The company recognizes the potential for significant changes in the market for approved products, which could impact future profitability [7]. - The company faces risks related to national policy changes, including stricter regulations on drug pricing and procurement processes, which could impact future growth [111]. - The demand for traditional Chinese medicine raw materials is rising, leading to potential price increases due to supply chain challenges [111]. Financial Performance - The company's operating revenue for 2018 was ¥3,419,750,405.17, a decrease of 8.36% compared to ¥3,731,602,626.26 in 2017 [23]. - The net profit attributable to shareholders was -¥147,444,710.73, representing a decline of 148.90% from ¥301,535,942.99 in the previous year [23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥178,929,496.00, down 166.28% from ¥269,940,615.62 in 2017 [23]. - The net cash flow from operating activities increased significantly to ¥154,477,419.28, a rise of 242.63% compared to ¥45,086,167.34 in 2017 [23]. - The total assets at the end of 2018 were ¥7,212,538,342.16, a decrease of 5.27% from ¥7,613,476,577.30 at the end of 2017 [23]. - The net assets attributable to shareholders decreased by 3.33% to ¥5,356,787,666.09 from ¥5,541,235,754.94 in 2017 [23]. Product Quality and Compliance - The company has experienced product quality issues, leading to product recalls and a commitment to enhance quality control measures to ensure patient safety [8]. - The company is committed to improving its product quality monitoring systems to prevent adverse reactions and ensure compliance with enhanced regulatory standards [8]. - The company has established a production traceability monitoring system for traditional Chinese medicine pieces [45]. - The company has implemented corrective measures to improve quality standards and production processes following regulatory scrutiny [180]. Research and Development - The company emphasizes the importance of selecting the right research and development projects to maintain core competitiveness and profitability amidst long approval cycles [7]. - The company is focusing on three major pipelines: "tumor," "urinary," and "tonic," while continuing to promote research and product internationalization [36]. - The company’s research and development continue to focus on generic drug consistency evaluation and deep research of existing varieties, with an emphasis on international certification and overseas cooperation [36]. - The company is committed to enhancing its research and development capabilities by attracting top talent and optimizing its R&D system [40]. - The company completed 125 R&D projects, focusing on consistency evaluation and deep research of existing products [72]. Marketing and Sales Strategy - The company has established a comprehensive marketing network, including prescription drug promotion, OTC brand operation, and exploring outpatient prescription sales [36]. - The marketing strategy will focus on building a clinical terminal network covering 5,000 hospitals and 50,000 experts and doctors, enhancing service-oriented marketing and collaboration with top pharmacy chains [107]. - The company intends to transform its sales approach from product-focused to culture, brand, quality, and service-oriented strategies, moving towards higher-level strategic competition [107]. - The company plans to enhance its project management and quality management systems to support the development of innovative drugs and consistent evaluation [107]. Investment and Financial Management - The company plans to continue expanding its production capabilities and product offerings, with ongoing projects in various stages of completion [90]. - The company has allocated RMB 310,887,900.00 to supplement working capital, indicating a focus on liquidity management [86]. - The company has made commitments regarding cash compensation for any penalties or losses incurred due to environmental compliance issues, with a 15-day response time for compensation after losses occur [129]. - The company is committed to using raised funds to supplement working capital without engaging in high-risk investments or providing financial assistance to others for 12 months [165]. Shareholder Relations and Profit Distribution - There will be no cash dividends or stock bonuses distributed to shareholders for the year [9]. - The company has a complete decision-making process for profit distribution, ensuring the protection of minority shareholders' rights [115]. - The company’s profit distribution plan for 2018 includes no cash dividends, no bonus shares, and no capital reserve conversion [118]. - The independent directors fulfilled their responsibilities and provided independent opinions on the profit distribution plan [115]. Legal and Compliance Issues - The company is involved in a legal dispute with a claimed amount of CNY 31.67 million, which has been recognized as a contingent liability [174]. - The company has established a commitment to provide accurate information and documentation related to major asset restructuring to relevant intermediary institutions [133]. - The company has been actively involved in legal proceedings, including a civil case that has reached the Supreme People's Court for review [178]. - The company reported a potential loss of CNY 13.2 million and another compensation of CNY 17.97 million due to a court ruling related to a contract dispute, which may adversely affect current or future profits [163]. Corporate Social Responsibility - The company has a long-standing commitment to poverty alleviation, integrating social responsibility into its corporate culture and operations [109]. - The company is enhancing its human resources management to attract and retain high-quality talent amid increasing competition in the pharmaceutical industry [111].

Financial Performance - Operating revenue increased by 1.04% to CNY 762,105,172.52 for the current period[7] - Net profit attributable to shareholders was a loss of CNY 30,773,631.40, a decrease of 137.68% year-on-year[7] - Basic earnings per share decreased by 118.96% to CNY -0.0298[7] - The company's total assets decreased to CNY 6,285,671,105.26 from CNY 6,539,515,178.11, a reduction of approximately 3.9%[58] - The net profit for the current period is a loss of CNY 57,701,430.96, compared to a profit of CNY 34,078,149.87 in the previous period, reflecting a negative shift in profitability[74] - The total comprehensive income for the current period is CNY 56,618,776.94, down from CNY 238,558,449.87 in the previous period[71] Cash Flow - Net cash flow from operating activities improved by 61.22% to CNY -57,790,876.40 year-to-date[7] - The total cash flow from operating activities shows a net outflow of CNY 57,790,876.40, an improvement from the previous period's outflow of CNY 149,032,135.74[75] - Cash inflow from operating activities totaled CNY 3,018,310,883.77, up from CNY 2,151,942,961.61 in the previous period[75] - The financing activities resulted in a net cash inflow of CNY 17,127,398.20, down from CNY 121,439,016.20 in the previous period[77] Shareholder Information - The total number of shareholders at the end of the reporting period was 23,325[11] - The largest shareholder, Shanxi Zhendong Health Industry Group Co., Ltd., holds 41.86% of the shares[11] - The company did not conduct any repurchase transactions among the top 10 shareholders during the reporting period[12] - Shareholders are restricted from transferring more than 25% of their total shares annually during their tenure, and no transfers are allowed within six months after leaving the company[40] Asset Management - Total assets decreased by 2.76% to CNY 7,403,128,792.36 compared to the end of the previous year[7] - Financial assets measured at fair value decreased by 91.60% to CNY 4,300,000 due to an increase in repurchased trading financial assets[19] - The company reported a significant risk of penalties due to the invalidity of land leasing agreements and potential construction violations[28] Investment and Expenses - Sales expenses for the first nine months of 2018 increased by 62.70% to CNY 1,175,436,009.07, driven by higher office, conference, training, service, consulting, and market operation costs[21] - Research and development expenses for the quarter were CNY 14,150,380.08, down from CNY 18,829,508.44, a decrease of about 25.3%[60] - The company incurred research and development expenses of CNY 18,771,420.75, slightly higher than CNY 17,968,574.41 in the previous period, reflecting ongoing investment in innovation[73] Compliance and Commitments - The company is committed to ensuring the accuracy and completeness of all financial documents and disclosures[30] - The company has committed to not engaging in high-risk investments or provide financial assistance to others within 12 months after using raised funds for working capital[45] - The company has established a commitment to not repurchase shares that were publicly issued prior to the IPO[41] - The company will ensure timely and lawful information disclosure as per regulatory requirements[37] Legal and Regulatory Issues - The company has not faced any criminal penalties or significant civil litigation in the past five years, indicating a stable legal standing[32] - There is a risk of administrative penalties from regulatory authorities due to potential non-compliance with environmental regulations[28] - Compensation responsibilities were outlined, with the company and its executives agreeing to cover 50% of actual losses incurred before December 31, 2017, and full compensation for losses occurring from January 1, 2018[29]